Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Zimmer Holdings, Inc.
Gel-One® Offers Knee Arthritis Sufferers Pain Relief and Restored Mobility in a Single Injection
CHICAGO, March 20, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, today introduced Gel-One® Cross-linked Hyaluronate at the 2013 American Academy of Orthopaedic Surgeons Annual Meeting. Gel-One Hyaluronate is an injectable gel approved for the treatment of osteoarthritis of the knee. The product is the first low-volume viscosupplement designed to provide pain relief and improve knee joint function through a single-injection treatment.
"Zimmer is committed to meeting osteoarthritis patients at every stage of the continuum of care, and this innovative cushioning gel offers therapy with the simplicity of a single, in-office injection," said David Nolan, Zimmer Senior Vice President. "Gel-One Hyaluronate is a supplement to natural synovial fluid, offering pain relief to patients living with knee osteoarthritis. We are excited to introduce this joint preservation technology to surgeons and their patients in the United States."
Gel-One Hyaluronate is indicated for the treatment of pain in knee osteoarthritis patients who have failed to respond to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs), or simple analgesics such as acetaminophen. Unlike other viscosupplement treatments, highly purified Gel-One Hyaluronate requires only 3mL for safe and effective treatment. Gel-One Hyaluronate is manufactured using a unique cross-linking process that enables increased viscoelasticity.
In a clinical study, Gel-One Hyaluronate demonstrated statistically significant pain relief over a Phosphate Buffered Saline control (PBS). Patients receiving Gel-One Hyaluronate experienced, on average, a nearly 40 percent reduction in pain from baseline (28 mm reduction in WOMAC pain on a 100 mm VAS, Visual Analog Scale).
For more information about Gel-One Hyaluronate, visit Zimmer at Booth 529 at the 2013 American Academy of Orthopaedic Surgeons annual meeting in Chicago, or go to www.zimmer.com.
Gel-One® is a registered trademark of Seikagaku Corporation.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2012 sales were approximately $4.5 billion. The Company is supported by the efforts of more than 8,500 employees worldwide.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
©2012 PR Newswire. All Rights Reserved.